INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/04/2026
Voltar para busca
Dado oficial do USPTO
GLYCOMAX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
10/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 29
Data de depósito
24/08/2016
Data de registro
17/07/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/01/2025
Última transação
10/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
AU
Examinador
NADELMAN, ANDREA KOYNER
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Probiotec Limited
Representantes
Jeffrey H. Greger Hauptman Ham, LLP
Classificação técnica
Classes Nice
Classe 5Classe 29
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substancesskincare preparations and substances; pharmaceutical preparations derived from dairy sources for skin care and the treatment of eczemapsoriasis and other skin conditions; pharmaceutical preparations for the therapeutic treatment of diabetes; pharmaceutical preparations for skin care and pharmaceutical preparations for application to the skin for skin carethe treatment of eczemapsoriasis and other skin conditions; pharmaceutical preparations for the treatment of dermatitis; pharmaceutical preparations for boosting the immune system; pharmaceutical preparations and products for treatment of metabolic disorders; pharmaceutical preparations and substances whose primary purpose is to boost metabolism or fat burning; pharmaceutical agents for activating metabolism; dietary medical preparations for slimming purposesincluding food supplements; dietary nutritional supplements not for medical purposes; dietetic substancesdietetic foods adapted for medical useincluding dietetic substances for use in weight control; dietetic foodstuffs for medical use in the form of prepared mealsdietetic foods adapted for medical use; dietetic beverages adapted for medical purposes; dietetic additives for foodmeal replacements in the nature of powdered nutrition and protein supplements; meal supplements in the nature of dietary supplements and other formulated powdered preparations in the nature of glucose for use as an additive to foods for medical purposes; protein for dietetic purposesprotein supplements; energy drinks in the nature of dietary supplemental drinks and energy drinks that are adapted for medical purposesdietary supplemental drinks; medicated preparations for use as additives for food for human consumptionvitamin preparations for use as a supplement for dietary supplements and infant formula; foods for persons having complex metabolic disordersmeal replacements in the nature of meal replacement bars adapted for medical usemeal supplements in the nature of nutritional supplement meal replacement bars for boosting energyother formulated powdered preparationspowdered dietary supplements; foodstuffs for use in the dietary management of obesityspecial dietary foodsbeverages and meal replacements in the nature of dietetic foodspasta adapted for medical usemeal replacement bars for weight loss purposes and meal replacement beverages adapted for medical use; health food supplements for persons with special dietary requirements; dried milk products for babiesdried milk powder for babies; milk foods for babies; human milk oligosaccharide dietary supplements; human milk oligosaccharide compoundsmilk sugar for medical purposes; human milk oligosaccharide additives for use as nutritional supplements in connection with pharmaceuticals and infant formula; human milk oligosaccharide additives for use as a dietary or nutritional supplement; human milk oligosaccharide compoundsmilk sugar for medical use; health food supplements and mineral supplementsmineral supplements for foodstuffs for human consumption; medicated mineral drinksmedicated mineral spring waters; nutritional supplementsnutritional supplements containing nut and fish oils; nutritional meal replacement powders in the nature of meal replacement powdered drink mixes adapted for medical use; nutritional meal replacementsnutritional meal replacement barsmilkshakes and other powdered preparations adapted for medical use for individuals preparing for or undergoing medical treatments; non-carbohydrate dietary supplements other than for medical use; powdered dietary food concentrates in the nature of dietary supplement drink mixes; powdered dietary food concentrates in the nature of weight management supplements for use in weight reduction programmes for medical purposes; preparations for use as additives to food for consumptionminerals and vitamin supplements; protein preparations in the nature of protein supplements for use as additives to foodstuffs for human consumption; protein based food preparationsbeing dietetic protein supplements and nutritional additives that are not for medical purposes in the nature of protein dietary supplements; slimming aids for medical useweight management products in the nature of dietary nutritional supplements; slimming preparations for medical usemeal replacement shakes for weight loss purposes; slimming products for medical usestimulatory medications for use in weight reduction programmes; vitamins and vitamin supplements; none of the foregoing goods including cell linesantibodies or proteins for pharmaceutical use
Classe 29
Dairy produce and dairy productsdairy-based beveragesdairy-based powders for making dairy-based food beverages and shake and dairy-based spreads; milk products excluding ice creamice milk and frozen yoghurt; milk; milk powder other than for babies; milk protein and milk protein products; milk powder replacers in the nature of milk powder; preparations for making milk based beverages in the nature of powdered milk; prepared meals consisting primarily of meatfruit or vegetables
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
21/03/2026
INPC
INVALIDATION PROCESSED
21/03/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
30/09/2025
C71T
CANCELLED SECTION 71
31/01/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
17/07/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/11/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
30/10/2018
FIMP
FINAL DISPOSITION PROCESSED
30/10/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/10/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
17/07/2018
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/06/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/06/2018
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
14/06/2018
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
10/06/2018
CHPB
POST PUBLICATION AMENDMENT - ENTERED
16/05/2018
APET
ASSIGNED TO PETITION STAFF
15/05/2018
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
27/04/2018
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
22/02/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/01/2018
PUBO
PUBLISHED FOR OPPOSITION
30/01/2018
GPNX
NOTIFICATION PROCESSED BY IB
26/01/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/01/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/01/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/01/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/12/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
18/12/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/12/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
18/12/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/12/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
20/06/2017
GNFR
FINAL REFUSAL E-MAILED
20/06/2017
CNFR
FINAL REFUSAL WRITTEN
20/06/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/05/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/05/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/05/2017
RFNT
REFUSAL PROCESSED BY IB
18/02/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/01/2017
RFRR
REFUSAL PROCESSED BY MPU
25/01/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/01/2017
CNRT
NON-FINAL ACTION WRITTEN
19/01/2017
MAFR
APPLICATION FILING RECEIPT MAILED
17/01/2017
DOCK
ASSIGNED TO EXAMINER
13/01/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/01/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/01/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GLYCOMAX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.